Programmatic Advertising in Healthcare: How It Works for Pharma, Providers, and Payers

People search "programmatic healthcare" expecting one playbook. There are at least five, and they overlap less than the label suggests. A specialty pharma brand reaching 4,000 rheumatologists has almost nothing in common, operationally, with a regional health system trying to fill its orthopedic surgery schedule, even if both run through the same DSP. This guide covers the shared machinery, then the parts that differ by advertiser type, then the decisions that tend to go wrong. The rest of the series goes deeper on each piece, and the existing pharma programmatic advertising guide covers the pharma side in more operational detail.

How programmatic advertising in healthcare works

The plumbing is standard. An advertiser or agency sets up campaigns in a demand-side platform (DSP). The DSP evaluates bid requests coming from supply-side platforms and exchanges, decides whether a given impression matches the targeting, and bids. Inventory can be bought in the open auction, through private marketplace (PMP) deals with selected publishers, or through programmatic guaranteed deals that lock in volume and price. If any of those terms are new, the pharma programmatic glossary defines more than forty of them in plain language.

Healthcare adds three layers on top of that plumbing:

• A data layer with legal limits. Who you can target, and with what data, depends on whether you are a drug maker, a HIPAA covered entity, or a consumer health app. The rules are different for each.
• A creative layer with mandatory review. Pharma and device ads go through medical, legal, and regulatory (MLR) review. Prescription drug ads carry fair balance and, for product claim ads, important safety information (ISI). Hospital ads have fewer federal rules but still go through compliance and brand review.
• A measurement layer tied to clinical events. The outcome you care about (a new prescription, a scheduled surgery, a plan enrollment) happens offline, often weeks after exposure, and the data that proves it is sensitive.

Most of the hard work in healthcare programmatic happens in those three layers, not in bid strategy.

Who uses healthcare programmatic, and for what

The table below is a simplified view. Real plans blur the lines, especially for telehealth companies that sell both prescriptions and services.

Two of these get their own articles in this series: programmatic advertising for hospitals and health systems, which spends most of its time on the HIPAA tracking question, and programmatic advertising for medical device marketing, where the audience is often a few hundred surgeons and the facilities that buy for them.

What makes healthcare programmatic different from other categories

If you come from retail or CPG, a few things will feel backwards.

Smaller audiences, higher value per person

An oncology brand might care about 15,000 prescribers in total. A rare-disease brand might care about a few hundred. Scale tactics that work for a soda brand (broad reach, cheap CPMs, heavy optimization toward clicks) produce waste here, because the DSP will happily find cheap impressions that are not your audience. Precision and match quality matter more than volume.

Creative that cannot be changed on the fly

Every version of an ad needs approval before it runs. That limits rapid creative testing, and it means dynamic creative has to work from pre-approved modules. The rules for that are covered in dynamic targeting and dynamic creative in pharma.

Data that carries legal risk

In most categories, a third-party interest segment is a commodity. In healthcare, a segment called "diagnosed with type 2 diabetes" raises questions about where the data came from, what consent sits behind it, and whether using it is legal in a given state. Washington's My Health My Data Act, for example, requires consent for collecting and sharing consumer health data, and other states have passed similar laws. Many brands now lean harder on contextual signals for consumer campaigns as a result; see pharma contextual advertising for how to build segments that hold up.

Outcomes you cannot see in the platform

A DSP can report clicks and site visits. It cannot report a new prescription. Outcomes come from separate measurement partners using claims, EHR, or other data, matched to exposure files. That is why measurement design is usually agreed before the campaign launches, not after.

Healthcare programmatic targeting: the main options

Healthcare programmatic targeting falls into a handful of families. Each trades precision against scale and privacy risk differently.

• NPI-based HCP targeting: a list of prescribers matched to digital identifiers. High precision, limited scale, match rates vary widely by partner.
• Condition or interest audiences: consumer segments built from purchase, survey, or modeled data. Useful for DTC; needs data provenance checks.
• Contextual: target the content, not the person. Lower privacy risk, sometimes lower precision.
• Endemic: buy space on medical publishers, EHR platforms, and point-of-care networks where the audience is already concentrated.
• Geographic: the default for hospitals and a useful layer for pharma when access or coverage varies by region.
• First-party, lookalike, and retargeting: powerful in other categories, restricted in healthcare depending on who you are and where the data came from.

The healthcare programmatic targeting options comparison puts all of these side by side on precision, scale, privacy risk, and measurement. The endemic question gets its own piece, endemic vs. non-endemic media for pharma, because it is often the biggest allocation decision in an HCP plan.

Channels: display is the smallest part now

Banner display still runs in nearly every plan, but most growth in healthcare programmatic has been in other formats:

• Connected TV and online video for DTC reach, with longer formats that can carry fair balance properly.
• Programmatic audio, including streaming music and podcasts, where the major statement has to be spoken and the runtime goes up accordingly.
• Digital out-of-home, including screens in pharmacies and medical office waiting rooms.
• Native and in-feed placements on health publishers.

Audio and DOOH have their own rules and measurement problems, covered in programmatic audio and digital out-of-home for healthcare.

How healthcare programmatic is measured

Measurement differs by advertiser, but the honest versions share one feature: a comparison group. Pharma brands typically send exposure files to an outcomes partner, which matches exposed HCPs or patients to claims or other data and compares prescribing against a holdout or matched control. Hospitals compare appointment requests in targeted ZIP codes to similar ZIP codes that were not targeted, or run on/off flights by market. Payers measure leads and enrollments, often within a short open enrollment window, which makes clean tests hard.

Data clean rooms have become a common way to do the matching without either party handing over raw records. They help with overlap analysis and some measurement, but they do not fix a weak test design. The data clean rooms for pharma media article covers what they solve and what they leave untouched.

Inventory quality and supply paths

Healthcare budgets are a target for low-quality supply because healthcare CPMs run higher than most categories. Made-for-advertising sites, resold inventory, and invalid traffic all show up in open-auction healthcare buys. The basic defenses are the same as anywhere: check ads.txt and sellers.json, prefer direct paths to publishers, use PMPs for important inventory, and review log-level data where you can get it. The difference is the cost of getting it wrong. Paying healthcare CPMs for impressions on a slideshow site with no physicians on it is a fast way to lose a budget review.

Compliance checkpoints for any healthcare programmatic campaign

1. Confirm which rules apply to your organization (FDA promotion rules, HIPAA, FTC, state health data laws, platform policies). They differ by advertiser type.
2. Get every creative version, including every dynamic combination, through MLR or compliance review.
3. Document the source and consent basis for every audience segment.
4. Review tags and pixels on landing pages before launch, especially for covered entities.
5. Agree the measurement plan and the data that will flow to measurement partners.
6. Set brand safety and suitability rules that block harmful adjacency without blocking all health content.

None of this is legal advice. It is the order in which a media team usually needs answers so the campaign can launch on time.

Practical takeaway

Before choosing a DSP, a data partner, or a channel mix, write one sentence that names your advertiser type, your audience unit (NPI, household, ZIP, or person), and the offline outcome you will measure against a comparison group. That sentence decides which targeting options are allowed, which inventory makes sense, and which measurement partner you need. Then use the targeting options comparison to pick the two or three tactics that fit it.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.